A clinical trial of empagliflozin, a sodium-glucose co-transporter 2 inhibitor, in addition to standard care in patients with type 2 diabetes at high cardiovascular risk has reported results in the New England Journal of Medicine. Patients were assigned to take either 10mg or 25mg empagliflozin per day, while a control group was given a placebo. The study reports that high-risk cardiovascular patients with type 2 diabetes who were taking empagliflozin had a reduced chance of cardiovascular events or death when compared with the placebo group.
Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl. Biomath., Theresa Devins, Dr.P.H., Odd Erik Johansen, M.D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., and Silvio E. Inzucchi, M.D. for the EMPA-REG OUTCOME Investigators “Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes” New England Journal of Medicine September 17, 2015DOI: 10.1056/NEJMoa1504720